文献
J-GLOBAL ID:201702254151276315
整理番号:17A1433294
行動への呼びかけ:初回臨床試験における高リスク骨髄異形成症候群の未治療患者の登録増加【Powered by NICT】
A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials
著者 (6件):
Zeidan Amer M.
(Department of Hematology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut)
,
Stahl Maximilian
(Department of Hematology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut)
,
Sekeres Mikkael A.
(Department of Hematology, Cleveland Clinic, Cleveland, Ohio)
,
Steensma David P.
(Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts)
,
Komrokji Rami S.
(H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida)
,
Gore Steven D.
(Department of Hematology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut)
資料名:
Cancer (Hoboken, N.J.)
(Cancer (Hoboken, N.J.))
巻:
123
号:
19
ページ:
3662-3672
発行年:
2017年
JST資料番号:
D0781B
ISSN:
0008-543X
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)